Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 15/20 | 0.51 |
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124016 | 0.82 | PDE10A (0.50) | PDE10AJAK2JAK3PTK2 | |
| SCHEMBL14124012 | 0.80 | PDE10A (0.56) | PDE10APDE4D | |
| Hydrochloric Acid SCHEMBL2034038 | 0.75 | PDE10A (0.50) | PDE10AJAK2JAK3PTK2 | |
| SCHEMBL1853624 | 0.72 | JAK2 (0.50) | PDE10AJAK2JAK3 | |
| SCHEMBL15033534 | 0.72 | PDE10A (0.41) | PDE10A | |
| SCHEMBL2040364 | 0.71 | PDE10A (0.57) | PDE10AJAK2JAK3 | |
| SCHEMBL1854893 | 0.69 | JAK2 (0.75) | PDE10AJAK2JAK3 | |
| SCHEMBL2251839 | 0.69 | JAK2 (0.50) | PDE10AJAK2JAK3 | |
| SCHEMBL15033533 | 0.69 | PDE10A (0.54) | PDE10A | |
| SCHEMBL1828295 | 0.68 | PDE10A (1.00) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927738-B2 | 2-arylimidazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-8785653-B2 | (3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2014-07-22 | — | — | US | disclosed |
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-20130281459-A1 | Heteroaromatic Aryl Triazole Derivatives as PDE10A Enzyme Inhibitors | H. LUNDBECK A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-8501795-B2 | (3-aryl-1H-1,2,4-triazol-5-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-8501797-B2 | (2-aryl-1H-imidazol-4-yl)-linked heterocycle derivatives | H. LUNDBECK A/S (DK) | 2013-08-06 | — | — | US | disclosed |
| US-20120309764-A1 | Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors | H. LUNDBECK A/S (DK) | 2012-12-06 | — | — | US | disclosed |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289038-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | PDE10A 5/4885JAK2 1217/4885JAK3 836/4885 |
| US-20130281459-A1 | Heteroaromatic Aryl Triazole Derivatives as PDE10A Enzyme Inhibitors | PDE5A, PDE3B, PDE3A | PDE10A 5/4885JAK2 1859/4885JAK3 894/4885 |
| US-20120309764-A1 | Heteroaromatic aryl triazole derivatives as PDE10A enzyme inhibitors | PDE5A, PDE3B, PDE3A | PDE10A 5/4885JAK2 1859/4885JAK3 894/4885 |
| US-20120302548-A1 | 2-ARYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS | PDE12, PDE3B, PDE5A | PDE10A 5/4885JAK2 1217/4885JAK3 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.